Influence of Age upon Ifosfamide-Induced Nephrotoxicity

Pediatric Blood and Cancer

Volumn 42, Issue 5, 2004, Pages 427-432

  McCune, Jeannine S ^a,c   Friedman, Debra L ^a,b   Schuetze, Scott ^a   Blough, David ^a   Magbulos, Madonna ^a   Hawkins, Douglas S ^a,b  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Ifosfamide; Nephrotoxicity; Pediatric; Renal

Indexed keywords

AMIFOSTINE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MESNA; VANCOMYCIN; VINCRISTINE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE PREDISPOSITION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; FEMALE; HUMAN; HYPOKALEMIA; HYPOPHOSPHATEMIA; INFANT; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NEPHROTOXICITY; PRIORITY JOURNAL; SARCOMA; SCORING SYSTEM;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; FEMALE; HUMANS; IFOSFAMIDE; INFANT; MALE; MIDDLE AGED; NEPHROSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SARCOMA;

EID: 1942519209     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20011     Document Type: Article

References (49)

1. Skinner R, Sharkey IM, Pearson AD, et al. Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol 1993;11:173-190.
2. Rossi R. Nephrotoxicity of ifosfamide-Moving towards understanding the molecular mechanisms [Editorial]. Nephrol Dial Transplant 1997;12:1091-1092.
3. Skinner R, Pearson AD, Price L, et al. Nephrotoxicity after ifosfamide. Arch Dis Child 1990;65:732-738.
4. Skinner R, Cotterill SJ, Stevens MC. Risk factors for nephrotoxicity after ifosfamide treatment in children: A UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group. Br J Cancer 2000;82:1636-1645.
5. Loebstein R, Atanackovic G, Bishai R, et al. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children. J Clin Pharmacol 1999;39:454-461.
6. Suarez A, McDowell H, Niaudet P, et al. Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: An International Society of Pediatric Oncology report. J Clin Oncol 1991;9:2177-2182.
7. Vassilopoulou-Sellin R, Brosnan P, Delpassand A, et al. Osteopenia in young adult survivors of childhood cancer. Med Pediatr Oncol 1999;32:272-278.
8. de Schepper J, Hachimi-Idrissi S, Louis O, et al. Bone metabolism and mineralisation after cytotoxic chemotherapy including ifosfamide. Arch Dis Child 1994;71:346-348.
9. Burk CD, Restaino I, Kaplan BS, et al. Ifosfamide-induced renal tubular dysfunction and rickets in children with Wilms tumor. J Pediatr 1990;117:331-335.
10. Garcia AA. Ifosfamide-induced Fanconi syndrome. Ann Pharmacother 1995;29:590-591.
11. Pratt CB, Meyer WH, Jenkins JJ, et al. Ifosfamide, Fanconi's syndrome, and rickets. J Clin Oncol 1991;9:1495-1499.
12. Moller TR, Garwicz S, Barlow L, et al. Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: A population-based study in the Nordic countries. J Clin Oncol 2001;19:3173-3181.
13. Hensley ML, Schuchter LM, Lindley C, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants [see Comments]. J Clin Oncol 1999;17:3333-3355.
14. Aleska K, Ito S, Goren G. Developmental Renal Tubular Toxicity: A Hypothetical Framework and Experimental Approaches. Cur Therap Workshop 2001;62:930-941.
15. Skinner R, Pearson AD, Price L, et al. The influence of age on nephrotoxicity following chemotherapy in children. Br J Cancer (Suppl) 1992;18:S30-S35.
16. Skinner R, Pearson AD, English MW, et al. Risk factors for ifosfamide nephrotoxicity in children [see Comments]. Lancet 1996;348:578-580.
17. Dubourg L, Taniere P, Cochat P, et al. Toxicity of chloroacetaldehyde is similar in adult and pediatric kidney tubules. Pediatr Nephrol 2002;17:97-103.
18. Kramer A, Goldschmidt H, Hahn U, et al. Progressive renal failure in two breast cancer patients after high-dose ifosfamide. Lancet 1994;344:1569.
19. Friedlaender MM, Haviv YS, Rosenmann E, et al. End-stage renal interstitial fibrosis in an adult ten years after ifosfamide therapy. Am J Nephrol 1998;18:131-133.
20. Le Cesne A, Judson I, Crowther D, et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the EORTC/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000;18:2676-2684.
21. Nichols CR, Catalano PJ, Crawford ED, et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: An Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study [see Comments]. J Clin Oncol 1998;16:1287-1293.
22. Hill PA, Prince HM, Power DA. Tubulointerstitial nephritis following high-dose ifosfamide in three breast cancer patients. Pathology 2000;32:166-170.
23. Bokemeyer C, Franzke A, Hartmann JT, et al. A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Cancer 1997;80:1221-1227.
24. Willemse PH, de Jong PE, Elema JD, et al. Severe renal failure following high-dose ifosfamide and mesna. Cancer Chemother Pharmacol 1989;23:329-330.
25. National Cancer Institute Common Toxicity Criteria (CTC). 1999; accessed on March 27, 2002. http://ctep.cancer.gov/reporting/ctc.html.
26. Marina NM, Poquette CA, Cain AM, et al. Comparative renal tubular toxicity of chemotherapy regimens including ifosfamide in patients with newly diagnosed sarcomas. J Pediatr Hematol Oncol 2000;22:112-118.
27. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003;348:694-701.
28. Womer RB, Daller RT, Fenton JG, et al. Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children. Eur J Cancer 2000;36:87-94.
29. Patel SR, Vadhan-Raj S, Burgess MA, et al. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol 1998;21:317-321.
30. Mohrmann M, Pauli A, Walkenhorst H, et al. Effect of ifosfamide metabolites on sodium-dependent phosphate transport in a model of proximal tubular cells (LLC-PK1) in culture. Ren Physiol Biochem 1993;16:285-298.
31. Springate JE. Ifosfamide metabolite chloroacetaldehyde causes renal dysfunction in vivo. J Appl Toxicol 1997;17:75-79.
32. Zamlauski-Tucker MJ, Morris ME, Springate JE. Ifosfamide metabolite chloroacetaldehyde causes Fanconi syndrome in the perfused rat kidney. Toxicol Appl Pharmacol 1994;129:170-175.
33. Singer JM, Hartley JM, Brennan C, et al. The pharmacokinetics and metabolism of ifosfamide during bolus and infusional administration: A randomized cross-over study. Br J Cancer 1998; 77:978-984.
34. Corlett SA, Parker D, Chrystyn H. Pharmacokinetics of ifosfamide and its enantiomers following a single 1 h intravenous infusion of the racemate in patients with small cell lung carcinoma. Br J Clin Pharmacol 1995;39:452-455.
35. Boddy AV, Proctor M, Simmonds D, et al. Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients. Eur J Cancer 1995;1:69-76.
36. Mohrmann M, Pauli A, Ritzer M, et al. Inhibition of sodium-dependent transport systems in LLC-PK1 cells by metabolites of ifosfamide [published Erratum appears in Renal Physiol Biochem 1994 Nov-Dec;17(6):332]. Ren Physiol Biochem 1992;15:289-301.
37. Mohrmann M, Pauli A, Ritzer M, et al. Inhibition of sodium-dependent transport systems in LLC-PK1 cells by metabolites of ifosfamide [published Erratum appears in Renal Physiol Biochem 1994 Nov-Dec;17(6):332]. Ren Physiol Biochem 1992;15:289-301.
38. Kurowski V, Cerny T, Kupfer A, et al. Metabolism and pharmacokinetics of oral and intravenous ifosfamide. J Cancer Res Clin Oncol 1991;117:S148-S153.
39. Wagner T, Heydrich D, Jork T, et al. Comparative study on human pharmacokinetics of activated ifosfamide and cyclophosphamide by a modified fluorometric test. J Cancer Res Clin Oncol 1981; 100:95-104.
40. Goren MP, Wright RK, Pratt CB, et al. Dechloroethylation of ifosfamide and neurotoxicity [Letter]. Lancet 1986;2:1219-1220.
41. Kaijser GP, Beijnen JH, Jeunink EL, et al. Determination of chloroacetaldehyde, a metabolite of oxazaphosphorine cytostatic drugs, in plasma. J Chromatogr 1993;614:253-259.
42. Kurowski V, Wagner T. Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother Pharmacol 1993;33:36-342.
43. Rossi R, Danzebrink S, Hillebrand D, et al. Ifosfamide-induced subclinical nephrotoxicity and its potentiation by cisplatinum. Med Pediatr Oncol 1994;22:27-32.
44. English MW, Skinner R, Pearson AD, et al. The influence of ifosfamide scheduling on acute nephrotoxicity in children. Br J Cancer 1997;75:1356-1359.
45. Raney B, Ensign LG, Foreman J, et al. Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor. Am J Pediatr Hematol Oncol 1994;16:286-295.
46. Goren MP, Wright RK, Horowitz ME, et al. Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna. Cancer Treat Rep 1987;71:127-130.
47. Petrilli AS, Oliveira DT, Ginani VC, et al. Use of amifostine in the therapy of osteosarcoma in children and adolescents. J Pediatr Hematol Oncol 2002;24:188-191.
48. Hartmann JT, Knop S, Fels LM, et al. The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors. Anticancer Drugs 2000;11:1-6.
49. de Kraker J, Bierings MB, Offringa M. Lack of protection of proximal tubular cells by amifostine (ethyol) in ifosfamide-containing regimens. Med Pediatr Oncol 2000;34:78-79.